Statistics

Total Visits

Views
Switching to dual therapy (atazanavir/ritonavir+lamivudine) vs. standard triple therapy (atazanavir/ritonavir+2 nucleos[t]ides) is safe and effective in virologically suppressed patients: 48-week results of a randomized clinical trial (SALT study)17

Select a period of time:

Number of views in the range

Views
Switching to dual therapy (atazanavir/ritonavir+lamivudine) vs. standard triple therapy (atazanavir/ritonavir+2 nucleos[t]ides) is safe and effective in virologically suppressed patients: 48-week results of a randomized clinical trial (SALT study)9

Views

Views
May 20242
June 20242
July 20240
August 20243
September 20242
October 20240
November 20240
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States9
 

Top cities views

Views
Chicago1